No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational, longitudinal study

BACKGROUND: To evaluate the impact of treatment with recombinant human growth hormone (rhGH; Omnitrope®) on the risk of diabetes mellitus in adults with growth hormone deficiency (GHD), using data from the ongoing PATRO Adults post-marketing surveillance study. METHODS: PATRO Adults is an ongoing po...

Descripción completa

Detalles Bibliográficos
Autores principales: Beck-Peccoz, Paolo, Höybye, Charlotte, Murray, Robert D., Simsek, Suat, Zabransky, Markus, Zouater, Hichem, Stalla, Günter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6907272/
https://www.ncbi.nlm.nih.gov/pubmed/31829160
http://dx.doi.org/10.1186/s12902-019-0464-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6907272/
https://www.ncbi.nlm.nih.gov/pubmed/31829160
http://dx.doi.org/10.1186/s12902-019-0464-2

Ejemplares similares